NASDAQ:AZRX AzurRx BioPharma (AZRX) Stock Price, News & Analysis → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free AZRX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.90▼$3.2450-Day Range$2.40▼$41.0052-Week Range$3.36▼$26.30Volume48,444 shsAverage Volume628,703 shsMarket Capitalization$28.16 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get AzurRx BioPharma alerts: Email Address Ad Prosper Trading AcademyThese AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free Copy About AzurRx BioPharma Stock (NASDAQ:AZRX)AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.Read More Ad Prosper Trading AcademyThese AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free Copy AZRX Stock News HeadlinesApril 11, 2024 | seekingalpha.comYS YS Biopharma Co., Ltd.April 19, 2023 | finance.yahoo.comHanAll Biopharma Opens Applications for the 2023 Pharmaceutical Industry Fellowship ProgramApril 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.January 15, 2023 | marketwatch.comFirst Wave BioPharma Shares Jump 21% on FDA Review of Adrulipase IND FilingSeptember 16, 2022 | seekingalpha.comFWBI First Wave BioPharma, Inc.April 30, 2022 | investing.comFirst Wave BioPharma Inc (FWBI)October 1, 2021 | reuters.comFirst Wave BioPharma IncSeptember 21, 2021 | marketwatch.comAzurRx BioPharma Changes Name to First Wave BioPharmaApril 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.September 21, 2021 | finance.yahoo.comAzurRx BioPharma to Change Corporate Name to First Wave BioPharma TodaySeptember 14, 2021 | benzinga.comAzurRx BioPharma To Acquire First Wave Bio In Transformative $229 Million Deal; Significantly Expands GI and IBD Treatment Pipeline (NASDAQ: AZRX)September 14, 2021 | msn.comWhy AzurRx BioPharma's Stock Is Trading Higher TodaySeptember 14, 2021 | finance.yahoo.comAzurRx (AZRX) Announces First Wave Bio Acquisition for $229MSeptember 14, 2021 | apnews.comAzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave ...September 14, 2021 | finance.yahoo.comAzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharmaSeptember 13, 2021 | finance.yahoo.comAzurRx BioPharma To Acquire First Wave Bio For $229MSeptember 13, 2021 | nasdaq.comAzurRx Announces Acquisition Of First Wave Bio, And Creation Of First Wave BioPharmaSeptember 13, 2021 | finanznachrichten.deAzurRx BioPharma, Inc.: AzurRx BioPharma Announces Reverse Stock SplitSeptember 13, 2021 | finance.yahoo.comAzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease IndicationsSeptember 10, 2021 | finance.yahoo.comAzurRx BioPharma Announces Reverse Stock SplitSeptember 10, 2021 | apnews.comAzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial ...September 10, 2021 | nasdaq.comAzurRx Activates New Clinical Trial Sites In India For Gastrointestinal Infections COVID-19 StudySeptember 10, 2021 | finance.yahoo.comAzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial Evaluating Niclosamide for the Treatment of COVID-19 Gastrointestinal InfectionsSeptember 9, 2021 | markets.businessinsider.comDMC Recommends AzurRx Continues Gastrointestinal Infections COVID-19 StudySeptember 9, 2021 | finance.yahoo.comAzurRx BioPharma Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal InfectionsSeptember 8, 2021 | finance.yahoo.comAzurRx BioPharma Submits an Investigational New Drug Application for Niclosamide as Treatment for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-Associated ColitisSeptember 7, 2021 | ca.finance.yahoo.comAzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment ConferenceSee More Headlines Receive AZRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AzurRx BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:AZRX CUSIPN/A CIK1604191 Webwww.azurrx.com Phone(649) 699-7855FaxN/AEmployees12Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($11.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,670,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-482.96% Return on Assets-258.47% Debt Debt-to-Equity RatioN/A Current Ratio1.33 Quick Ratio1.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.76) per share Price / Book-3.97Miscellaneous Outstanding Shares9,326,000Free Float8,645,000Market Cap$28.16 million OptionableNot Optionable Beta1.51 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesJames E. SapirsteinChairman, President & Chief Executive OfficerDaniel H. SchneidermanChief Financial OfficerJames E. PenningtonChief Medical OfficerTony BacaVice President-Clinical OperationsMartin KrusinSenior Vice President-Corporate DevelopmentKey CompetitorsAprea TherapeuticsNASDAQ:APRELexaria BioscienceNASDAQ:LEXXSpruce BiosciencesNASDAQ:SPRBDaré BioscienceNASDAQ:DARENRx PharmaceuticalsNASDAQ:NRXPView All Competitors AZRX Stock Analysis - Frequently Asked Questions When did AzurRx BioPharma's stock split? AzurRx BioPharma shares reverse split on Monday, September 13th 2021. The 1-10 reverse split was announced on Monday, September 13th 2021. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 13th 2021. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of AzurRx BioPharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other AzurRx BioPharma investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), SCYNEXIS (SCYX), Gran Tierra Energy (GTE), Cogent Biosciences (UMRX), KushCo (KSHB), Organigram (OGI), Pennsylvania Real Estate Investment Trust (PEI) and Novan (NOVN). When did AzurRx BioPharma IPO? AzurRx BioPharma (AZRX) raised $15 million in an initial public offering on Friday, September 9th 2016. The company issued 2,100,000 shares at a price of $6.00-$8.00 per share. WallachBeth Capital and Network 1 Financial Securities acted as the underwriters for the IPO. This page (NASDAQ:AZRX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsThe World's First "$20 Trillion Drug?"Behind the MarketsI’m afraid WWIII is a very real possibility Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AzurRx BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
